| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Accounting Officer & VP
1 company
Ted Monohon last filed a Form 4 in March 2023, as Chief Accounting Officer & VP at QNCX. Ted Monohon's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 27,440 shares of QNCX. The QNCX filings lean toward selling, a net 1,871 shares.
Ted Monohon has 9 Form 4 filings on record from February 2021 to March 2023, all as Chief Accounting Officer & VP at Quince Therapeutics (QNCX), 2021–2023.
The 9 reported transactions were 4 option or other derivative awards, 3 tax withholdings, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $2K.
The only open-market sale was 1,871 shares of QNCX at an average $0.98 on March 6, 2023, about $2K. Twelve months later QNCX was up 21%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2023 | QNCX Quince Therapeutics, Inc. | Chief Accounting Officer & VP | Sell | 1,871 | $0.98 | $1,833.58 | -6.4% | +46.4% | +21.3% |